Patents by Inventor Fumie Jimma
Fumie Jimma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11155519Abstract: By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer.Type: GrantFiled: April 23, 2018Date of Patent: October 26, 2021Assignees: OTSUKA PHARMACEUTICAL FACTORY, INC., ADABIO CO., LTD.Inventors: Katsuya Hiraishi, Hiroyuki Soma, Fumie Jimma, Taro Adachi, Ippei Yamaoka, Naoyuki Endo
-
Patent number: 11001573Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: GrantFiled: October 15, 2019Date of Patent: May 11, 2021Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
-
Patent number: 10610558Abstract: The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.Type: GrantFiled: November 25, 2016Date of Patent: April 7, 2020Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
-
Publication number: 20200055821Abstract: By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer.Type: ApplicationFiled: April 23, 2018Publication date: February 20, 2020Applicants: OTSUKA PHARMACEUTICAL FACTORY, INC., ADABIO CO., LTD.Inventors: Katsuya HIRAISHI, Hiroyuki SOMA, Fumie JIMMA, Taro ADACHI, Ippei YAMAOKA, Naoyuki ENDO
-
Publication number: 20200039964Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: ApplicationFiled: October 15, 2019Publication date: February 6, 2020Applicants: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya HIRAISHI, Fumie JIMMA, Hiroyuki SOMA, Taro ADACHI, Masakazu ADACHI, Ippei YAMAOKA, Tomohiro KAGAWA
-
Patent number: 10494362Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: GrantFiled: November 1, 2016Date of Patent: December 3, 2019Assignees: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya Hiraishi, Fumie Jimma, Hiroyuki Soma, Taro Adachi, Masakazu Adachi, Ippei Yamaoka, Tomohiro Kagawa
-
Publication number: 20180334452Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).Type: ApplicationFiled: November 1, 2016Publication date: November 22, 2018Applicants: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya HIRAISHI, Fumie JIMMA, Hiroyuki SOMA, Taro ADACHI, Masakazu ADACHI, Ippei YAMAOKA, Tomohiro KAGAWA
-
Publication number: 20180325975Abstract: The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.Type: ApplicationFiled: November 25, 2016Publication date: November 15, 2018Applicants: ADABIO CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Katsuya HIRAISHI, Fumie JIMMA, Hiroyuki SOMA, Taro ADACHI, Masakazu ADACHI, Ippei YAMAOKA, Tomohiro KAGAWA
-
Patent number: 9506927Abstract: Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable.Type: GrantFiled: November 25, 2015Date of Patent: November 29, 2016Assignee: On-Chip Biotechnologies Co., Ltd.Inventors: Kazuo Takeda, Fumie Jimma, Masashi Takao
-
Publication number: 20160146825Abstract: Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable.Type: ApplicationFiled: November 25, 2015Publication date: May 26, 2016Applicant: ON-CHIP BIOTECHNOLOGIES CO., LTD.Inventors: Kazuo TAKEDA, Fumie JIMMA, Masashi TAKAO
-
Patent number: 9341550Abstract: Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable.Type: GrantFiled: November 21, 2011Date of Patent: May 17, 2016Assignee: ON-CHIP BIOTECHNOLOGIES CO., LTD.Inventors: Kazuo Takeda, Fumie Jimma, Masashi Takao
-
Publication number: 20130302828Abstract: Conventional CTC detection methods have been problematic in that 1) there is no technique for automatically determining and counting live CTCs in a brief period of time, 2) no process has been developed for detecting, counting, and thereafter collecting and culturing live CTCs, and 3) there exists no flow cytometer that is contamination free and is capable of measuring an entire sample. Provided is a CTC detection method which comprises a pre-treatment step for concentrating and fluorescence staining CTCs, and a step for identifying and counting CTCs. The pre-treatment step includes attaching magnetic beads to EpCAM antibodies expressed by epithelial cell-derived CTCs and concentrating the CTCs through the use of a magnet, fluorescently labeling an epithelia cell surface marker of the CTCs through the use of EpCAM antibodies or 5E11 antibodies, and performing two types of nuclear staining, one being cell membrane-permeable and the other being cell membrane-impermeable.Type: ApplicationFiled: November 21, 2011Publication date: November 14, 2013Applicant: ON-CHIP BIOTECHNOLOGIES CO., LTD.Inventors: Kazuo Takeda, Fumie Jimma, Masashi Takao